With funding and support from the Climate and Sustainability Translational Fund, researchers will pursue green jet fuel, cleaner chemicals, sustainable packaging, and carbon storage.

Attivare Therapeutics, a Harvard startup out of the Wyss Institute, has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS), Dana-Farber Cancer Institute, and Massachusetts General Hospital. This technology creates an in vivo training ground for the immune system to fight cancer more effectively and prevent infection.

GC Therapeutics (GCTx), a Harvard startup, announced its launch to scale and its technology TFome™, the world’s first “plug and play” induced pluripotent stem cell (iPSC) programming platform for cell therapies in multiple therapeutic areas. 

Harvard researchers have pioneered a groundbreaking method for generating large numbers of adult skeletal-muscle satellite cells, also known as muscle stem cells, in vitro.